Concepts (305)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Soil | 11 | 2025 | 72 | 4.550 |
Why?
|
| Intestinal Diseases, Parasitic | 11 | 2025 | 34 | 4.410 |
Why?
|
| Parasites | 9 | 2025 | 37 | 4.170 |
Why?
|
| Helminths | 12 | 2025 | 46 | 4.080 |
Why?
|
| Real-Time Polymerase Chain Reaction | 15 | 2025 | 545 | 3.410 |
Why?
|
| Helminthiasis | 10 | 2025 | 77 | 3.160 |
Why?
|
| Feces | 22 | 2025 | 783 | 2.490 |
Why?
|
| DNA, Helminth | 5 | 2024 | 23 | 2.420 |
Why?
|
| Strongyloides stercoralis | 9 | 2025 | 20 | 1.780 |
Why?
|
| Chagas Disease | 4 | 2025 | 309 | 1.770 |
Why?
|
| DNA, Protozoan | 6 | 2025 | 32 | 1.700 |
Why?
|
| Anthelmintics | 3 | 2024 | 55 | 1.530 |
Why?
|
| Strongyloidiasis | 6 | 2020 | 16 | 1.490 |
Why?
|
| Coinfection | 5 | 2024 | 182 | 1.340 |
Why?
|
| Rural Population | 8 | 2024 | 280 | 1.310 |
Why?
|
| Trypanosoma cruzi | 4 | 2025 | 251 | 1.310 |
Why?
|
| Trichuris | 4 | 2025 | 26 | 1.290 |
Why?
|
| Hookworm Infections | 4 | 2024 | 123 | 1.250 |
Why?
|
| Antigens, Protozoan | 2 | 2025 | 80 | 1.160 |
Why?
|
| Trichuriasis | 2 | 2025 | 31 | 1.110 |
Why?
|
| Taenia solium | 3 | 2015 | 11 | 1.060 |
Why?
|
| Dengue | 2 | 2025 | 122 | 1.050 |
Why?
|
| Animals | 43 | 2025 | 36222 | 1.050 |
Why?
|
| Sensitivity and Specificity | 14 | 2025 | 2153 | 1.040 |
Why?
|
| Neurocysticercosis | 2 | 2015 | 27 | 0.930 |
Why?
|
| Leishmaniasis | 1 | 2025 | 40 | 0.930 |
Why?
|
| Dog Diseases | 1 | 2025 | 58 | 0.920 |
Why?
|
| Ivermectin | 1 | 2024 | 8 | 0.920 |
Why?
|
| Albendazole | 1 | 2024 | 29 | 0.910 |
Why?
|
| Hemoglobins | 1 | 2025 | 322 | 0.850 |
Why?
|
| Sanitation | 2 | 2025 | 17 | 0.790 |
Why?
|
| Prevalence | 11 | 2025 | 2639 | 0.790 |
Why?
|
| Isosporiasis | 1 | 2021 | 3 | 0.750 |
Why?
|
| Brugia malayi | 1 | 2022 | 40 | 0.750 |
Why?
|
| Giardia lamblia | 5 | 2023 | 10 | 0.750 |
Why?
|
| Ecuador | 6 | 2025 | 15 | 0.730 |
Why?
|
| Mycobacterium tuberculosis | 5 | 2024 | 408 | 0.720 |
Why?
|
| Immunocompromised Host | 2 | 2021 | 305 | 0.710 |
Why?
|
| Eosinophilia | 2 | 2021 | 86 | 0.710 |
Why?
|
| Poverty | 2 | 2024 | 438 | 0.690 |
Why?
|
| Intestines | 3 | 2020 | 599 | 0.680 |
Why?
|
| Diarrhea | 2 | 2023 | 339 | 0.670 |
Why?
|
| Beds | 1 | 2020 | 9 | 0.670 |
Why?
|
| Parasite Egg Count | 5 | 2024 | 26 | 0.660 |
Why?
|
| Dust | 1 | 2020 | 18 | 0.660 |
Why?
|
| Sarcoma, Kaposi | 1 | 2021 | 137 | 0.660 |
Why?
|
| Vitamin B 12 | 1 | 2020 | 62 | 0.650 |
Why?
|
| Gastrointestinal Hemorrhage | 1 | 2021 | 244 | 0.630 |
Why?
|
| Family Characteristics | 1 | 2020 | 91 | 0.630 |
Why?
|
| HIV Infections | 3 | 2024 | 2075 | 0.620 |
Why?
|
| Organ Transplantation | 1 | 2020 | 183 | 0.570 |
Why?
|
| Humans | 53 | 2025 | 133811 | 0.560 |
Why?
|
| Parasite Load | 1 | 2017 | 31 | 0.560 |
Why?
|
| Tuberculosis | 5 | 2024 | 553 | 0.550 |
Why?
|
| Ancylostomatoidea | 2 | 2024 | 60 | 0.520 |
Why?
|
| Nucleic Acid Amplification Techniques | 3 | 2024 | 72 | 0.500 |
Why?
|
| Pilot Projects | 5 | 2025 | 1491 | 0.490 |
Why?
|
| Hypereosinophilic Syndrome | 2 | 2013 | 9 | 0.480 |
Why?
|
| Child | 18 | 2025 | 25882 | 0.470 |
Why?
|
| Tuberculosis, Pulmonary | 3 | 2024 | 228 | 0.460 |
Why?
|
| DNA | 2 | 2022 | 1683 | 0.460 |
Why?
|
| Antibodies, Protozoan | 2 | 2025 | 95 | 0.460 |
Why?
|
| Developed Countries | 1 | 2014 | 42 | 0.450 |
Why?
|
| Emigration and Immigration | 1 | 2014 | 81 | 0.440 |
Why?
|
| Alabama | 3 | 2025 | 47 | 0.420 |
Why?
|
| Parasitic Diseases | 1 | 2014 | 62 | 0.420 |
Why?
|
| Cysticercosis | 1 | 2013 | 22 | 0.420 |
Why?
|
| Global Health | 2 | 2017 | 622 | 0.410 |
Why?
|
| Female | 25 | 2025 | 71840 | 0.410 |
Why?
|
| Granuloma | 1 | 2013 | 64 | 0.410 |
Why?
|
| Brain Edema | 1 | 2013 | 71 | 0.410 |
Why?
|
| Developing Countries | 1 | 2014 | 290 | 0.390 |
Why?
|
| Child, Preschool | 11 | 2025 | 14878 | 0.390 |
Why?
|
| Ascaris lumbricoides | 3 | 2018 | 19 | 0.380 |
Why?
|
| Gastrointestinal Microbiome | 1 | 2020 | 822 | 0.380 |
Why?
|
| Calcinosis | 1 | 2013 | 191 | 0.370 |
Why?
|
| Serologic Tests | 3 | 2025 | 128 | 0.370 |
Why?
|
| Adrenal Cortex Hormones | 2 | 2013 | 343 | 0.370 |
Why?
|
| Antibodies, Helminth | 4 | 2025 | 120 | 0.370 |
Why?
|
| Adult | 17 | 2025 | 31823 | 0.370 |
Why?
|
| Malaria, Falciparum | 1 | 2012 | 72 | 0.360 |
Why?
|
| Neglected Diseases | 1 | 2014 | 152 | 0.360 |
Why?
|
| Plasmodium falciparum | 1 | 2012 | 97 | 0.360 |
Why?
|
| Cryptosporidium | 3 | 2017 | 33 | 0.360 |
Why?
|
| Schistosomiasis | 2 | 2024 | 54 | 0.360 |
Why?
|
| Environment | 2 | 2024 | 154 | 0.350 |
Why?
|
| Giardiasis | 2 | 2023 | 9 | 0.350 |
Why?
|
| Ancylostomiasis | 2 | 2024 | 62 | 0.350 |
Why?
|
| Young Adult | 8 | 2025 | 9926 | 0.340 |
Why?
|
| Adolescent | 11 | 2025 | 20610 | 0.340 |
Why?
|
| Molecular Diagnostic Techniques | 3 | 2024 | 179 | 0.330 |
Why?
|
| Male | 21 | 2025 | 65939 | 0.330 |
Why?
|
| Anti-Infective Agents | 2 | 2022 | 277 | 0.310 |
Why?
|
| Enzyme-Linked Immunosorbent Assay | 4 | 2025 | 842 | 0.300 |
Why?
|
| Antigens, Helminth | 2 | 2025 | 183 | 0.290 |
Why?
|
| Middle Aged | 13 | 2025 | 29287 | 0.290 |
Why?
|
| Seizures | 1 | 2013 | 889 | 0.290 |
Why?
|
| Anemia, Sickle Cell | 1 | 2012 | 346 | 0.290 |
Why?
|
| Blastocystis | 3 | 2025 | 6 | 0.280 |
Why?
|
| Ancylostoma | 3 | 2024 | 98 | 0.280 |
Why?
|
| Urban Population | 3 | 2020 | 243 | 0.280 |
Why?
|
| Ascariasis | 2 | 2018 | 73 | 0.260 |
Why?
|
| Infant | 5 | 2025 | 13246 | 0.260 |
Why?
|
| Seroepidemiologic Studies | 2 | 2025 | 144 | 0.260 |
Why?
|
| Cross-Sectional Studies | 5 | 2025 | 3739 | 0.250 |
Why?
|
| Entamoeba histolytica | 2 | 2017 | 14 | 0.240 |
Why?
|
| Sputum | 2 | 2024 | 116 | 0.240 |
Why?
|
| Recombinant Proteins | 3 | 2025 | 1433 | 0.240 |
Why?
|
| Texas | 3 | 2025 | 3720 | 0.240 |
Why?
|
| Sewage | 1 | 2025 | 11 | 0.240 |
Why?
|
| Species Specificity | 3 | 2017 | 563 | 0.240 |
Why?
|
| Peru | 1 | 2025 | 56 | 0.240 |
Why?
|
| Leishmania | 1 | 2025 | 35 | 0.230 |
Why?
|
| Necator americanus | 2 | 2017 | 89 | 0.230 |
Why?
|
| Protozoan Infections | 1 | 2025 | 16 | 0.230 |
Why?
|
| South Carolina | 1 | 2024 | 10 | 0.230 |
Why?
|
| Schistosoma | 1 | 2024 | 13 | 0.220 |
Why?
|
| Mississippi | 1 | 2024 | 35 | 0.220 |
Why?
|
| Dogs | 1 | 2025 | 672 | 0.220 |
Why?
|
| Louisiana | 1 | 2024 | 137 | 0.220 |
Why?
|
| Mexico | 1 | 2024 | 190 | 0.220 |
Why?
|
| Emigrants and Immigrants | 2 | 2020 | 155 | 0.220 |
Why?
|
| Dengue Virus | 1 | 2025 | 134 | 0.220 |
Why?
|
| Inflammation | 3 | 2020 | 1570 | 0.210 |
Why?
|
| Hematopoietic Stem Cell Transplantation | 1 | 2012 | 1191 | 0.210 |
Why?
|
| Water | 1 | 2024 | 199 | 0.200 |
Why?
|
| Pyrethrins | 1 | 2022 | 13 | 0.200 |
Why?
|
| Mycobacterium bovis | 1 | 2022 | 31 | 0.200 |
Why?
|
| Arboviruses | 1 | 2022 | 27 | 0.190 |
Why?
|
| Receptors, Interleukin-5 | 1 | 2022 | 5 | 0.190 |
Why?
|
| Immunoglobulin G | 1 | 2025 | 791 | 0.190 |
Why?
|
| Interleukin-5 | 1 | 2022 | 48 | 0.190 |
Why?
|
| Insecticides | 1 | 2022 | 62 | 0.190 |
Why?
|
| Isospora | 1 | 2021 | 3 | 0.190 |
Why?
|
| Uganda | 2 | 2024 | 89 | 0.190 |
Why?
|
| BCG Vaccine | 2 | 2022 | 112 | 0.180 |
Why?
|
| Trimethoprim, Sulfamethoxazole Drug Combination | 1 | 2021 | 45 | 0.180 |
Why?
|
| Aedes | 1 | 2022 | 109 | 0.180 |
Why?
|
| Rabbits | 1 | 2022 | 710 | 0.180 |
Why?
|
| Longitudinal Studies | 1 | 2025 | 1516 | 0.170 |
Why?
|
| Zika Virus | 1 | 2022 | 151 | 0.170 |
Why?
|
| Blastocystis Infections | 1 | 2020 | 5 | 0.170 |
Why?
|
| Laboratory Proficiency Testing | 1 | 2020 | 10 | 0.170 |
Why?
|
| Toxocara | 1 | 2020 | 12 | 0.170 |
Why?
|
| Controlled Clinical Trials as Topic | 1 | 2020 | 13 | 0.170 |
Why?
|
| Zika Virus Infection | 1 | 2022 | 175 | 0.170 |
Why?
|
| Environmental Microbiology | 1 | 2020 | 16 | 0.170 |
Why?
|
| RNA Interference | 1 | 2022 | 547 | 0.160 |
Why?
|
| Eosinophils | 1 | 2020 | 108 | 0.160 |
Why?
|
| Genes, Bacterial | 1 | 2020 | 218 | 0.160 |
Why?
|
| Metagenomics | 1 | 2020 | 110 | 0.160 |
Why?
|
| Argentina | 2 | 2017 | 54 | 0.150 |
Why?
|
| CD4 Lymphocyte Count | 2 | 2017 | 237 | 0.150 |
Why?
|
| Colombia | 3 | 2024 | 48 | 0.150 |
Why?
|
| Schistosoma haematobium | 1 | 2018 | 18 | 0.150 |
Why?
|
| Whole Genome Sequencing | 1 | 2020 | 325 | 0.140 |
Why?
|
| Mass Drug Administration | 1 | 2018 | 12 | 0.140 |
Why?
|
| Genetic Variation | 1 | 2025 | 1630 | 0.140 |
Why?
|
| Microbiota | 1 | 2023 | 443 | 0.140 |
Why?
|
| Th1 Cells | 1 | 2018 | 159 | 0.140 |
Why?
|
| Microscopy | 2 | 2020 | 123 | 0.130 |
Why?
|
| Treatment Outcome | 2 | 2024 | 13114 | 0.130 |
Why?
|
| Risk Factors | 3 | 2025 | 11166 | 0.130 |
Why?
|
| Reproducibility of Results | 2 | 2015 | 3047 | 0.130 |
Why?
|
| Entamoeba | 1 | 2016 | 3 | 0.130 |
Why?
|
| Antiretroviral Therapy, Highly Active | 1 | 2017 | 272 | 0.120 |
Why?
|
| RNA, Messenger | 1 | 2022 | 2885 | 0.120 |
Why?
|
| Aged | 4 | 2025 | 21714 | 0.120 |
Why?
|
| Linear Models | 1 | 2017 | 721 | 0.120 |
Why?
|
| Head Movements | 1 | 2015 | 27 | 0.120 |
Why?
|
| United States | 4 | 2015 | 11760 | 0.120 |
Why?
|
| Vertigo | 1 | 2015 | 35 | 0.120 |
Why?
|
| Cerebral Ventricles | 1 | 2015 | 84 | 0.110 |
Why?
|
| Latin America | 1 | 2014 | 98 | 0.110 |
Why?
|
| Headache | 1 | 2015 | 110 | 0.110 |
Why?
|
| Africa | 1 | 2014 | 141 | 0.110 |
Why?
|
| Asia | 1 | 2014 | 126 | 0.110 |
Why?
|
| Vomiting | 1 | 2015 | 110 | 0.110 |
Why?
|
| Mozambique | 2 | 2024 | 23 | 0.110 |
Why?
|
| Parasitology | 1 | 2014 | 7 | 0.110 |
Why?
|
| CD4-Positive T-Lymphocytes | 1 | 2017 | 509 | 0.110 |
Why?
|
| DNA Primers | 2 | 2013 | 671 | 0.110 |
Why?
|
| Cysticercus | 1 | 2013 | 2 | 0.110 |
Why?
|
| Europe | 1 | 2014 | 380 | 0.100 |
Why?
|
| Mali | 1 | 2013 | 12 | 0.100 |
Why?
|
| Empirical Research | 1 | 2013 | 9 | 0.100 |
Why?
|
| Poverty Areas | 2 | 2025 | 32 | 0.100 |
Why?
|
| Honduras | 2 | 2025 | 25 | 0.100 |
Why?
|
| Cohort Studies | 3 | 2018 | 5219 | 0.100 |
Why?
|
| Diagnostic Tests, Routine | 1 | 2014 | 135 | 0.100 |
Why?
|
| Data Collection | 1 | 2014 | 399 | 0.100 |
Why?
|
| Antinematodal Agents | 1 | 2012 | 11 | 0.100 |
Why?
|
| India | 1 | 2013 | 239 | 0.100 |
Why?
|
| Retrospective Studies | 4 | 2025 | 17577 | 0.100 |
Why?
|
| Sierra Leone | 1 | 2012 | 31 | 0.100 |
Why?
|
| North America | 1 | 2013 | 266 | 0.100 |
Why?
|
| Health Status | 1 | 2014 | 414 | 0.100 |
Why?
|
| High-Throughput Screening Assays | 1 | 2013 | 110 | 0.100 |
Why?
|
| Syndrome | 1 | 2015 | 1175 | 0.090 |
Why?
|
| Neuroimaging | 1 | 2015 | 376 | 0.090 |
Why?
|
| Drug Administration Schedule | 1 | 2013 | 748 | 0.090 |
Why?
|
| DNA, Bacterial | 2 | 2024 | 491 | 0.090 |
Why?
|
| Early Diagnosis | 1 | 2012 | 201 | 0.090 |
Why?
|
| DNA Methylation | 1 | 2018 | 1146 | 0.090 |
Why?
|
| Chronic Disease | 2 | 2013 | 1234 | 0.090 |
Why?
|
| Surveys and Questionnaires | 2 | 2020 | 4006 | 0.090 |
Why?
|
| Zoonoses | 2 | 2024 | 52 | 0.090 |
Why?
|
| Acquired Immunodeficiency Syndrome | 1 | 2012 | 238 | 0.090 |
Why?
|
| Epstein-Barr Virus Infections | 1 | 2013 | 293 | 0.080 |
Why?
|
| Hypersensitivity | 1 | 2012 | 195 | 0.080 |
Why?
|
| Recurrence | 1 | 2013 | 1470 | 0.080 |
Why?
|
| Acute Disease | 1 | 2012 | 1185 | 0.080 |
Why?
|
| Aged, 80 and over | 2 | 2017 | 7195 | 0.070 |
Why?
|
| Prospective Studies | 3 | 2024 | 6602 | 0.070 |
Why?
|
| Immunosuppressive Agents | 1 | 2012 | 679 | 0.070 |
Why?
|
| Diagnosis, Differential | 1 | 2012 | 1973 | 0.060 |
Why?
|
| Genotype | 1 | 2012 | 2819 | 0.060 |
Why?
|
| Soil Microbiology | 1 | 2025 | 15 | 0.060 |
Why?
|
| Drinking Water | 1 | 2025 | 17 | 0.060 |
Why?
|
| Interferon-gamma | 2 | 2018 | 536 | 0.060 |
Why?
|
| Eosinophil Cationic Protein | 1 | 2004 | 1 | 0.060 |
Why?
|
| Schistosoma mansoni | 1 | 2004 | 24 | 0.060 |
Why?
|
| Immunoassay | 1 | 2025 | 137 | 0.060 |
Why?
|
| Schistosomiasis mansoni | 1 | 2004 | 24 | 0.060 |
Why?
|
| Polymerase Chain Reaction | 2 | 2020 | 1616 | 0.060 |
Why?
|
| Pets | 1 | 2024 | 17 | 0.060 |
Why?
|
| Giardia | 1 | 2023 | 1 | 0.050 |
Why?
|
| Tanzania | 1 | 2024 | 73 | 0.050 |
Why?
|
| Magnetic Resonance Imaging | 1 | 2015 | 3869 | 0.050 |
Why?
|
| Multicenter Studies as Topic | 1 | 2024 | 296 | 0.050 |
Why?
|
| Phenazines | 1 | 2022 | 9 | 0.050 |
Why?
|
| Brain | 1 | 2015 | 3223 | 0.050 |
Why?
|
| Alginates | 1 | 2022 | 25 | 0.050 |
Why?
|
| Insecticide Resistance | 1 | 2022 | 39 | 0.050 |
Why?
|
| Mucins | 1 | 2022 | 77 | 0.050 |
Why?
|
| Tryptophan | 1 | 2022 | 100 | 0.050 |
Why?
|
| Mosquito Vectors | 1 | 2022 | 37 | 0.050 |
Why?
|
| Pathology, Molecular | 1 | 2022 | 67 | 0.050 |
Why?
|
| Swine | 1 | 2025 | 1205 | 0.050 |
Why?
|
| Metabolic Networks and Pathways | 1 | 2022 | 197 | 0.050 |
Why?
|
| ATP-Binding Cassette Transporters | 1 | 2022 | 198 | 0.040 |
Why?
|
| Multiplex Polymerase Chain Reaction | 1 | 2020 | 33 | 0.040 |
Why?
|
| New York City | 1 | 2020 | 65 | 0.040 |
Why?
|
| Spatial Analysis | 1 | 2020 | 25 | 0.040 |
Why?
|
| Chicago | 1 | 2020 | 21 | 0.040 |
Why?
|
| Antitubercular Agents | 1 | 2022 | 265 | 0.040 |
Why?
|
| Gene Expression | 1 | 2004 | 1611 | 0.040 |
Why?
|
| Escherichia coli | 1 | 2025 | 1031 | 0.040 |
Why?
|
| Bacteria | 1 | 2022 | 537 | 0.040 |
Why?
|
| Receptors, Cytokine | 1 | 2018 | 68 | 0.040 |
Why?
|
| Colony Count, Microbial | 1 | 2018 | 86 | 0.040 |
Why?
|
| Limit of Detection | 1 | 2018 | 77 | 0.040 |
Why?
|
| Antibiotics, Antitubercular | 1 | 2018 | 34 | 0.040 |
Why?
|
| Interleukin-4 | 1 | 2018 | 148 | 0.040 |
Why?
|
| Timor-Leste | 1 | 2017 | 1 | 0.030 |
Why?
|
| World Health Organization | 1 | 2018 | 119 | 0.030 |
Why?
|
| Polymorphism, Restriction Fragment Length | 1 | 2017 | 152 | 0.030 |
Why?
|
| High-Throughput Nucleotide Sequencing | 1 | 2022 | 964 | 0.030 |
Why?
|
| Program Development | 1 | 2018 | 190 | 0.030 |
Why?
|
| Interleukin-12 | 1 | 2017 | 122 | 0.030 |
Why?
|
| Interleukin-2 | 1 | 2017 | 245 | 0.030 |
Why?
|
| Interleukin-10 | 1 | 2017 | 189 | 0.030 |
Why?
|
| Healthy Volunteers | 1 | 2016 | 153 | 0.030 |
Why?
|
| Drug Resistance, Bacterial | 1 | 2018 | 384 | 0.030 |
Why?
|
| Biomarkers | 1 | 2025 | 3422 | 0.030 |
Why?
|
| Pandemics | 1 | 2022 | 1193 | 0.030 |
Why?
|
| Phylogeny | 1 | 2017 | 781 | 0.030 |
Why?
|
| Tumor Necrosis Factor-alpha | 1 | 2017 | 686 | 0.030 |
Why?
|
| C-Reactive Protein | 1 | 2017 | 470 | 0.030 |
Why?
|
| Mice | 3 | 2023 | 18936 | 0.030 |
Why?
|
| Mice, Inbred C57BL | 1 | 2023 | 4823 | 0.030 |
Why?
|
| Leukemic Infiltration | 1 | 2013 | 8 | 0.030 |
Why?
|
| Randomized Controlled Trials as Topic | 1 | 2017 | 1221 | 0.020 |
Why?
|
| Disease Models, Animal | 1 | 2023 | 4760 | 0.020 |
Why?
|
| Cells, Cultured | 1 | 2018 | 3144 | 0.020 |
Why?
|
| Animal Structures | 1 | 2011 | 14 | 0.020 |
Why?
|
| Alum Compounds | 1 | 2011 | 42 | 0.020 |
Why?
|
| HIV | 1 | 2012 | 193 | 0.020 |
Why?
|
| Anti-Retroviral Agents | 1 | 2012 | 154 | 0.020 |
Why?
|
| Practice Guidelines as Topic | 1 | 2018 | 1340 | 0.020 |
Why?
|
| Larva | 1 | 2011 | 254 | 0.020 |
Why?
|
| Cell Proliferation | 1 | 2018 | 2559 | 0.020 |
Why?
|
| Infant, Newborn | 1 | 2023 | 8632 | 0.020 |
Why?
|
| Viral Load | 1 | 2012 | 411 | 0.020 |
Why?
|
| RNA, Viral | 1 | 2012 | 562 | 0.020 |
Why?
|
| Skin | 1 | 2013 | 543 | 0.020 |
Why?
|
| Anti-Inflammatory Agents | 1 | 2012 | 314 | 0.020 |
Why?
|
| Adjuvants, Immunologic | 1 | 2011 | 391 | 0.020 |
Why?
|
| Mice, Inbred BALB C | 1 | 2011 | 1083 | 0.020 |
Why?
|
| HIV-1 | 1 | 2012 | 489 | 0.020 |
Why?
|
| Transcription Factors | 1 | 2018 | 2730 | 0.020 |
Why?
|
| Survival Analysis | 1 | 2011 | 1593 | 0.020 |
Why?
|
| Follow-Up Studies | 1 | 2015 | 5455 | 0.010 |
Why?
|
| Blotting, Northern | 1 | 2004 | 269 | 0.010 |
Why?
|
| Immunoblotting | 1 | 2004 | 316 | 0.010 |
Why?
|
| T-Lymphocytes | 1 | 2013 | 1770 | 0.010 |
Why?
|
| Selection, Genetic | 1 | 2004 | 169 | 0.010 |
Why?
|
| Spleen | 1 | 2004 | 287 | 0.010 |
Why?
|
| Sequence Alignment | 1 | 2004 | 631 | 0.010 |
Why?
|
| Evolution, Molecular | 1 | 2004 | 710 | 0.010 |
Why?
|
| Amino Acid Sequence | 1 | 2004 | 2785 | 0.010 |
Why?
|
| Base Sequence | 1 | 2004 | 3169 | 0.010 |
Why?
|
| Molecular Sequence Data | 1 | 2004 | 3966 | 0.010 |
Why?
|
| Sequence Analysis, DNA | 1 | 2004 | 1834 | 0.010 |
Why?
|
| Liver | 1 | 2004 | 1860 | 0.010 |
Why?
|